Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences

SAN DIEGO,Calif.,SUZHOU and SHANGHAI,China,June. 14,2022 -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"),a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer,today announced that the management team will participate in and attend one-on-one meetings at three investor conferences in June 2022 as follows:

Goldman Sachs Virtual Healthcare Corporate Day

One-on-one meetings: June 20 - 24

Truist Securities Cell Therapy Symposium - symposia-cel (in person)

One-on-one meetings: June 28

Location: New York,NY

Stifel 2022 Virtual Cell Therapy Summit

Panel: June 30 at 11:30 am ET

Corporate Panel: Allogeneic CAR-T – What Have We Learned,and Where are We Going

About Gracell

Gracell Biotechnologies Inc.("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CARTTMtechnology module,Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies,including lengthy manufacturing time,suboptimal cell quality,high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell,please visitwww.gracellbio.com.Follow @GracellBio onLinkedIn.

Media contact

Marvin Tang

marvin.tang@gracellbio.com

Investor contact

Gracie Tong

gracie.tong@gracellbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/gracell-biotechnologies-to-participate-in-three-upcoming-investor-conferences-301567117.html